BOSTON — As Biogen’s new CEO Chris Viehbacher pores over Biogen’s books and scouts out M&A deals, he may have one advantage his predecessor didn’t: a good relationship with his board of directors.
Investors have expressed hope over the last several years that Biogen would make more acquisition deals, but it’s been a point of contention within the company. Biogen’s last chief executive, Michel Vounatsos, and his business development team put together proposals for several deals, but were often stymied by dueling factions on the board of directors, STAT reported last year.
But Viehbacher has inherited a different board: In March, the company announced that Caroline Dorsa would take over as board chair from Stelios Papadopoulos.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect